Global News

SAFC to support next-gen NSAID product development

Monday, November 5, 2012 11:16 AM

Sigma-Aldrich’s custom manufacturing and services business unit, SAFC, has signed an agreement with South Korea-based CrystalGenomics, a clinical stage biopharmaceutical company, to support the development of active pharmaceutical ingredients (APIs) for next-generation non-steroidal anti-inflammatory drugs (NSAID).

More... »

Ziarco founded with Series A financing

Monday, November 5, 2012 11:01 AM

Recently founded Ziarco, a clinical-stage biotech focused on therapeutics targeting inflammatory and allergic diseases, has closed an initial $6 million tranche of Series A financing totaling $27 million. The round was led by Biotechnology Value Fund, with participation by Pfizer Venture Investments.

More... »

Icon reports Q3 revenue of $286M

Monday, November 5, 2012 09:24 AM

Icon, a global provider of outsourced development services, reported its financial results for the third quarter ended September 30, 2012. Net revenues for the quarter grew 19% to $286 million compared to $241 million in the same quarter last year.

More... »

Nimbus Discovery names Lynch as executive chairman

Friday, November 2, 2012 03:04 PM

Nimbus Discovery, a biotechnology company based in Cambridge, Mass., has appointed Daniel S. Lynch to the company's board of directors as executive chairman. Lynch will succeed Bruce Booth, D. Phil., co-founder of Nimbus and partner at Atlas Venture, who will remain on the board.

More... »

Bayer HealthCare strengthens position in Russia

Friday, November 2, 2012 02:21 PM

Bayer HealthCare and Russian drug manufacturer Medsintez have entered into a strategic partnership to jointly manufacture and commercialize diagnostic imaging products as well as pharmaceuticals to treat infections and neural disorders.

More... »

Portola, BMS, Pfizer ink collaboration on study on reversing anticoagulation

Friday, November 2, 2012 01:57 PM

Portola Pharmaceuticals, a therapeutics company focused on thrombosis, inflammatory disease and cancer, global biopharmaceutical company Bristol-Myers Squibb (BMS) and Pfizer have signed a clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor Elquis (apixaban).

More... »

Vertex, GSK partner on phase II all-oral study of VX-135, GSK2336805 for Hep C

Friday, November 2, 2012 11:23 AM

Vertex Pharmaceuticals, a global biotechnology company based in Cambridge, Mass., has entered into a non-exclusive agreement with GlaxoSmithKline (GSK) to conduct a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing Vertex's nucleotide analogue HCV polymerase inhibitor VX-135 and GSK's NS5A inhibitor GSK2336805.

More... »

Ensemble, Boehringer Ingelheim collaborate on macrocycle drug candidates

Friday, November 2, 2012 10:56 AM

Ensemble Therapeutics of Cambridge, Mass., has initiated a research collaboration with Germany-based Boehringer Ingelheim to discover drug candidates of a novel class of small molecule drugs, called macrocycles, against several high-value pharmaceutical targets specified by Boehringer Ingelheim.

More... »

FDA grants Bayer’s Stivarga NDA priority review

Thursday, November 1, 2012 11:49 AM

Bayer HealthCare and Onyx Pharmaceuticals, a biopharmaceutical company based in South San Francisco, announced today that the FDA has granted priority review to the New Drug Application (NDA) for Stivarga (regorafenib) tablets.

More... »

Aesica wins European Outsourcing award for UCB acquisition strategy

Thursday, November 1, 2012 10:53 AM

Aesica, a global contract manufacturing organization, has won the European Outsourcing award for ‘best acquisition’ following the successful acquisition and integration of three different UCB sites—at Monheim and Zwickau, Germany, and Pianezza in, Italy, in 2011.

More... »